Urology
Volume 68, Issue 6 , Pages 1188-1192 , December 2006

Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer

  • Henry K. Tsai

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Henry K. Tsai, M.D., Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox LL, Boston, MA 02114.
    • ,
  • Matthew S. Katz

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • John J. Coen

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Anthony L. Zietman

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Donald S. Kaufman

      Affiliations

    • Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • William U. Shipley

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Received 19 April 2006 ,Accepted 17 August 2006.

References 

  1. Shipley WU, Prout GR, Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931–935
  2. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62–67
  3. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–3071
  4. Shipley WU, Kaufman DS, Tester WJ, et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003;97:2115–2119
  5. FitzGerald TJ, Daugherty C, Kase K, et al. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate: implications for increased therapeutic ratio of low dose rate irradiation. Am J Clin Oncol. 1985;8:517–522
  6. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science. 1988;239:645–647
  7. Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000;60:6597–6600
  8. McKenna WG, Muschel RJ, Gupta AK, et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene. 2003;22:5866–5875
  9. Miller AC, Kariko K, Myers CE, et al. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer. 1993;53:302–307
  10. Graaf MR, Richel DJ, van Noorden CJ, et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev. 2004;30:609–641
  11. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005;2:82–89
  12. Sleijfer S, van der Gaast A, Planting AS, et al. The potential of statins as part of anti-cancer treatment. Eur J Cancer. 2005;41:516–522
  13. Stamm JA, Ornstein DL. The role of statins in cancer prevention and treatment. Oncology. 2005;19:739–750
  14. Jakobisiak M, Bruno S, Skierski JS, et al. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA. 1991;88:3628–3632
  15. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology. 2005;66:1209–1212
  16. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–491
  17. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs. 2001;19:81–83
  18. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer. 2001;84:886–891
  19. Katz MS, Zelefsky MJ, Marion C, et al. Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer. (abstract) Int J Radiat Oncol Biol Phys. 2003;57:S271
  20. Katz MS, Minsky BD, Saltz LB, et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:1363–1370
  21. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology. 2005;66:1150–1154
  22. Winquist E, Moore MJ, Chi KN, et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol. 2005;23:143–149
  23. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271
  24. Aznar S, Fernandez-Valeron P, Espina C, et al. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 2004;206:181–191
  25. Miller GE, Stagnitti MN. Trends in Statin Use in the Civilian Noninstitutionalized Medicare Population, 1997 and 2002. Rockville, MD: Agency for Healthcare Research and Quality; 2005;http://www.meps.ahrq.gov/papers/st97/stat97.pdf. Accessed January 27, 2006.

PII: S0090-4295(06)02073-5

doi: 10.1016/j.urology.2006.08.1078

Urology
Volume 68, Issue 6 , Pages 1188-1192 , December 2006

Article Tools

* Image Usage & Resolution